Current Tendencies in Psychopharmacology of Dual Psychosis
International Journal of Dual Diagnosis
Volume 1, Issue 1, March 2016, Pages: 9-13
Received: Mar. 3, 2016; Accepted: Mar. 11, 2016; Published: Apr. 14, 2016
Views 3802      Downloads 211
Portilla Fernández A., Mental Health Net, Department of Psychiatry, Pamplona, Navarra, Spain
García Nicolás M., Mental Health Net, Department of Psychiatry, Tudela, Navarra, Spain
Article Tools
Follow on us
The treatment of people suffering a Dual psychotic disorder is a real challenge for the clinical staff. MAny of clinical considers this disorder as very severe because patients presents a wide range of symptoms with a high intensity, adherence to treatment is very low and many tmes is necessary to employ the psychiatric admissions as only way to treat this problema. We carry outa review of recent publiciations about psychopharmacological and psychological treatment, citing some international guide about wich are te most effective treatment of this kind of patients
Dual Psychosis, Psychopharmacology, Long Acting Antipscyhotic Treatment
To cite this article
Portilla Fernández A., García Nicolás M., Current Tendencies in Psychopharmacology of Dual Psychosis, International Journal of Dual Diagnosis. Vol. 1, No. 1, 2016, pp. 9-13. doi: 10.11648/j.ijdd.20160101.12
Copyright © 2016 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License ( which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Sepede G, Lorusso M, Spano MC, Di Iorio G, Martinotti G, et al.(2014) Substance Use in Schizophrenia: Efficacy of Atypical Antipsychotics. J Schizophr Res, 1(1): 1-12.
Lisa Dixon. (1999) Dual diagnosis of substance abuse in schizophrenia: prevalence and impact on outcomes. Schizophrenia Research. Volume 35, Supplement 1, Pages S93–S100.
Jennifer p. Wisdom. (2011). Substance Use Disorder Among People with First-Episode Psychsis: A systematic Review of Courseand Treatment. Psychiatric services (Washington DC)., pp 1007-1012.
Blum K, Oscar Berman M. (2014). Hypothesizing dopaminergic genetic antecedents in schizophrenia and substance seeking behavior. Med Hypotheses: 606-14.
Fernandez-Espejo E, Viveros MP, Núñez L. (2009). Role of cannabis and endocannabinoids in the genesis of schizophrenia. Psychopharmacology (Berl): 531-49.
The World Journal of Biological Psychiatry, 2015; 16:142-170 (TREATMENT GUIDELINES) World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia. Part 3: Update 2015 Management of special circumstances: Depression, Suicidality, substance use disorders andpregnancy and lactation
Schnell T, Koethe D, Krasnianski A, Gairing S, Schnell K, Daumann J, Gouzoulis-Mayfrank E. (2014) Ziprasidone versus clozapine in the treatment of dually diagnosed (DD) patients with schizophrenia and cannabis use disorders: a randomized study. Am J Addict: 308-12.
Koola MM, Wehring HJ, Kelly DL. (2012). The Potential Role of Long-acting Injectable Antipsychotics in People with Schizophrenia and Comorbid Substance Use. J Dual Diagn.; 8(1): 50-61.
Beresford TP, Clapp L, Martin B, Wiberg JL, Alfers J, Beresford HF. (2005) Aripiprazole in schizophrenia with cocaine dependence: a pilot study. J Clin Psychopharmacol. 25(4):363-6.
Psychosis with coexisting substance misuse: Assessment and management in adults and young people NICE guidelines [CG120] Published date: March 2011.
Núnez Domínguez, García María del Carmen. (2014). Palmitato of paliperidone in dual pathology. A retrospective study. Adicciones Intepsiquis 2014. Congreso Virtual de Psiquiatría.
Ikeda T, Koike J, Kouda M, Inamoto A, Morota N. (2014). Investigation of community support measures for patients with comorbid substance use disorder and psychotic disorder: nationwide survey of drug addiction rehabilitation centers. Nihon Arukoru Yakubutsu Igakkai Zasshi.
Boden MT, Moos R. (2013). Predictors of substance use disorder treatment outcomes among patients with psychotic disorders. Schizophr Res. 2013 May
Bartoli F, Scarone S, Clerici M. (2013). Risk of hospitalization among patients with co-occurring psychotic and substance use disorders: a 12-year follow-up. Riv Psichiatr. ;48(1):51-9.
Grau-López L, Roncero C, Daigre C, Miquel L, Barral C, Gonzalvo B, Collazos F, Casas M. (2014). Observational study on medications prescribed to dual-diagnosis outpatients. J Addict Med.;8(2):84-9.
Murthy P, Chand P. (2012). Treatment of dual diagnosis disorders. Curr Opin Psychiatry; 25(3):194-200.
Bruno A, Romeo VM, Pandolfo G, Scimeca G, Zoccali RA, Muscatello MR. (2014). Aripiprazole plus topiramate in opioid-dependent patients with schizoaffective disorder: an 8-week, open label, uncontrolled preliminary study. Subst Abus.; 35(2): 119-21
Schnell T, Koethe D, Krasnianski A, Gairing S, Schnell K, Daumann J, Gouzoulis-Mayfrank E. (2014). Ziprasidone versus clozapine in the treatment of dually diagnosed (DD) patients with schizophrenia and cannabis use disorders: a randomized study. Am J Addict.;23(3):308-12
Ben-Zeev D, Kaiser SM, Krzos I. (2014). Remote "hovering" with individuals with psychotic disorders and substance use: feasibility, engagement, and therapeutic alliance with a text-messaging mobile interventionist. J. Dual Diagn. 10(4):197-203.
Samaha AN. (2014). Can antipsychotic treatment contribute to drug addiction in schizophrenia? Prog Neuropsychopharmacol Biol Psychiatry. 3;52:9-16.
Science Publishing Group
1 Rockefeller Plaza,
10th and 11th Floors,
New York, NY 10020
Tel: (001)347-983-5186